Vaxcyte, Inc. (PCVX)

NASDAQ: PCVX · USD

$61.4

+0.76 (+1.3%)· Recorded snapshot

Market cap	9.7B
Net income (ttm)	-1.1B
EPS (ttm)	-$7.65
Shares out	157.4M
Volume	1,783,540
Beta	1.23

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -1.1B
EPS (ttm): -$7.65
Market cap: 9.7B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Mantener

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 13.4P50 20.2P75 35.7

Trailing P/En/a

P25 15.4P50 25.8P75 43.5

ROE-36.5

P25 -113.8P50 -46.5P75 -0.9

ROIC-24.2

P25 -68.5P50 -27.1P75 1.8

Benchmarks · 1M

All PCVX indicators

Market & fundamental data

Available fields

180

Groups with data

Currency

USD

Showing 180 of 180 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001649094
Company name	Vaxcyte, Inc.
Country	United States
Country code	US
CUSIP number	92243G108
Earnings date	2026-11-10
Earnings time	amc
Employees	507
Employees change	93
Employees growth	22.46%
Enterprise value	$8.3B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2013
In index	RUSSELL2000
Industry	Biotechnology
IPO date	2020-06-12
Is primary listing	Yes
Is SPAC	No
ISIN number	US92243G1085
Last 10-K release date	2026-02-24
Last earnings date	2026-08-05
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$9.7B
Market cap category	Mid-Cap
Next earnings date	2026-11-10
Options	Yes
Price	$61.43
Price currency	USD
Sector	Healthcare
SIC code	2836
Stock price date	2026-10-28
Symbol	PCVX
U.S. state	California
Website	https://vaxcyte.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-12.45%
FCF / EV yield	-11.36%
FCF yield	-9.72%
P/B ratio	3.19x
Price / tangible book value	3.44x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Profit per employee	$-2.1M
ROA	-22.61%
ROA (5Y)	-19.26%
ROCE	-40.65%
ROE	-36.51%
ROE (5Y)	-30.11%
ROIC	-24.15%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	0
Net income growth years	0
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-39.8M
Depreciation and amortization	$16.5M
EBIT	$-1.2B
EBITDA	$-1.1B
EPS	$-7.65
FCF per share	$-5.85
Financing cash flow	$606M
Free cash flow	$-921.1M
Free cash flow minus SBC	$-1.1B
Investing cash flow	$150.6M
Net cash flow	$-123.4M
Net income	$-1.1B
Operating cash flow minus SBC	$-1B
Operating income	$-1.2B
Stock-based compensation	$150.5M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Book value per share	$19.05
Debt / equity	0.04
Long-term assets	$1.6B
Long-term liabilities	$108.9M
Net cash (debt)	$1.4B
Net cash / market cap	14.47%
Net cash growth	-12.96%
Net debt / equity	-0.5
Piotroski F-Score	1
Property, plant and equipment	$370.6M
Shareholders' equity	$2.8B
Tangible book value	$2.8B
Tangible book value per share	$19.05
Total assets	$3.1B
Total cash	$1.5B
Total debt	$115.4M
Total liabilities	$380.2M
WACC	10.91%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current assets	$1.6B
Current liabilities	$271.3M
Current ratio	5.72
Net working capital	$-198.9M
Quick ratio	5.48
Working capital	$1.3B

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-4.88%
Dividend yield	0%
Shareholder yield	-4.88%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$57.38
1D price change	1.25%
1M price change	8.68%
1M total return	8.68%
1W price change	-7.76%
1W total return	-7.76%
1Y price change	37.07%
1Y return CAGR	37.1%
1Y total return	37.07%
20-day SMA	$64.42
200-day SMA	$56.89
3M price change	10.07%
3M total return	10.07%
3Y price change	29.98%
3Y return CAGR	9.13%
3Y total return	29.98%
50-day SMA	$61.60
50-day SMA vs 200-day SMA	50over200
52-week high	$90.75
52-week high date	2026-10-05
52-week low	$39.87
52-week low date	2025-11-05
5Y price change	177.43%
5Y return CAGR	22.64%
5Y total return	177.43%
6M price change	2.29%
6M total return	2.29%
All-time high	$121.06
All-time high date	2024-09-19
All-time low	$15.51
All-time low date	2021-05-11
Average true range (ATR)	$3.82
Average volume	3.9M
Beta (1Y)	1.32
Beta (2Y)	2.03
Beta (5Y)	1.23
Change from 52-week high	-32.31%
Change from 52-week low	54.08%
Change from all-time high	-49.54%
Change from all-time low	293.87%
Change from open	2.18%
Day's gap	-0.91%
Dollar volume	$109.6M
High price	$61.62
Low price	$59.99
Monthly RSI	53.72
Open price	$60.12
Position in 52-week range	88.34%
Premarket change	0.54%
Premarket close	$60.67
Premarket price	$61.00
Premarket volume	748
Previous close	$60.67
Price vs 150-day SMA	6.46%
Price vs 20-day SMA	-5.17%
Price vs 200-day SMA	7.39%
Price vs 50-day SMA	-0.82%
Relative volume	0.45
Return from IPO open	189.57%
Return from IPO price	276.44%
RSI	46.88
Sharpe ratio	0.76
Sharpe ratio (3Y)	0.4
Sharpe ratio (5Y)	0.57
Sortino ratio	1.48
Sortino ratio (3Y)	0.68
Sortino ratio (5Y)	1.01
Volume	1.8M
Weekly RSI	53.8
YTD price change	32.4%
YTD total return	32.4%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	145M
Float percentage	92.12%
Shares change (QoQ)	3.58%
Shares change (YoY)	4.88%
Shares held by insiders	0.59%
Shares held by institutions	100.38%
Shares outstanding	157.4M
Short % of float	11.93%
Short % of shares	10.99%
Short ratio	12.2 days

Deeper analysis on PCVX

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this PCVX report

Is a complete PCVX research report available?

No complete published report is available for Vaxcyte, Inc. (PCVX) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Vaxcyte, Inc. (PCVX)

Price

Financial snapshot

Fair-value bridge

Latest news · PCVX

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All PCVX indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on PCVX

Frequently asked questions